Dengue Fever Vaccine: Towards Low Cost Production And Delivery
Funder
National Health and Medical Research Council
Funding Amount
$612,039.00
Summary
With rising populations and a warming climate mosquito borne viral diseases will become more prevalent and low-cost vaccine production & delivery systems will become increasingly important. Here a microalgae based vaccine production platform will be coupled to proven Nanopatch & low cost oral vaccine delivery. The focus is on a Dengue virus vaccine, as Dengue causes 400 million infections & 100 million symptomatic cases annually.
Improving Oocyte Mitochondrial DNA Copy Number To Enhance Female Reproductive Capacity.
Funder
National Health and Medical Research Council
Funding Amount
$670,867.00
Summary
Eggs with too few copies of mitochondrial DNA either fail to fertilise or arrest during early development. By supplementing eggs with mitochondrial DNA, we have been able to enhance embryo quality and gene expression profiles. By breeding the offspring derived from eggs given mitochondrial supplementation, we will determine if they and their progeny meet normal developmental milestones, regulate the transmission of mitochondrial DNA appropriately, and are healthy and fertile.
A Novel Vaccine Formaultion To Prevent Birth Defects
Funder
National Health and Medical Research Council
Funding Amount
$530,922.00
Summary
Congenital cytomegalovirus (CMV) infection is one of the TORCH infections (toxoplasmosis, rubella, cytomegalovirus, and herpes simplex) and is one of major cause of birth defects. Transmission of CMV infection from mother to unborn babies can lead to deafness, blindness, small head syndrome (microcephaly), seizures and mental retardation. There is an urgent need to develop an effective vaccine against CMV. This project is aiming to develop a novel CMV vaccine formulation for clinical testing in ....Congenital cytomegalovirus (CMV) infection is one of the TORCH infections (toxoplasmosis, rubella, cytomegalovirus, and herpes simplex) and is one of major cause of birth defects. Transmission of CMV infection from mother to unborn babies can lead to deafness, blindness, small head syndrome (microcephaly), seizures and mental retardation. There is an urgent need to develop an effective vaccine against CMV. This project is aiming to develop a novel CMV vaccine formulation for clinical testing in humans.Read moreRead less
We will work with Coridon Pty Ltd to optimize the practical administration of a vaccine designed to cure people already infected with cancer-promoting papilloma viruses.
Development Of A Novel Microfluidic Device To Treat Male Infertility
Funder
National Health and Medical Research Council
Funding Amount
$508,397.00
Summary
This research aims to develop a novel technology for the separation of high quality sperm. It is envisaged this will replace existing technology to improve the reproductive outcomes of both humans, as well as animals.
Nicotinamide Adenine Dinucleotide (NAD+)-raising Agents For Improving Oocyte Quality
Funder
National Health and Medical Research Council
Funding Amount
$445,827.00
Summary
Many women cannot have children because of suboptimal egg quality, often due to aging. Currently, the only option is to use better quality eggs donated from another woman. This project will use pharmacological agents to promote recently discovered pathways in eggs central to determining quality. Importantly, we will investigate a simple and practical approach that can be used in clinics for augmenting these pathways to improve oocyte quality for the first time.
Infertility is common and although IVF is widely accepted, the procedure is expensive and is associated with health risks. Using laboratory animals, we have made significant advances towards developing new technologies that can mature eggs and produce embryos in vitro, but without women receiving hormone injections. This project will seek means to combine the benefits of two of our existing technologies into one integrated system, to provide hormone-free infertility treatment.